Warfarin

Generic Name
Warfarin
Brand Names
Coumadin, Jantoven
Drug Type
Small Molecule
Chemical Formula
C19H16O4
CAS Number
81-81-2
Unique Ingredient Identifier
5Q7ZVV76EI
Background

Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.

Indication

Indicated for:

1) Prophylaxis and treatment of venous thromboembolism and related pulmonary embolism.

2) Prophylaxis and treatment of thromboembolism associated with atrial fibrillation.

3) Prophylaxis and treatment of thromboembolism associated with cardiac valve replacement.

4) Use as adjunct therapy to reduce mortality, recurrent myocardial infarction, and thromboembolic events post myocardial infarction.

Off-label uses include:

1) Secondary prevention of stroke and transient ischemic attacks in patients with rheumatic mitral valve disease but without atrial fibrillation.

Associated Conditions
Myocardial Infarction, Pulmonary Embolism, Stroke, Systemic Embolism, Thromboembolism, Transient Ischemic Attack, Venous Thrombosis (Disorder)
Associated Therapies
-

Study of the Effects of ITCA 650 on Gastric Emptying and Interaction of ITCA 650 on 4 Commonly Studied Drugs

First Posted Date
2015-12-30
Last Posted Date
2017-01-27
Lead Sponsor
Intarcia Therapeutics
Target Recruit Count
33
Registration Number
NCT02641899
Locations
🇺🇸

Quintiles, Overland Park, Kansas, United States

Length of Stay in NVAF Patients Hospitalized and Initiated With Dabigatran or Warfarin in Japan

First Posted Date
2015-12-15
Last Posted Date
2018-03-30
Lead Sponsor
Boehringer Ingelheim
Target Recruit Count
4313
Registration Number
NCT02631057
Locations
🇯🇵

NISED Center, Tokyo, Shinagawa, Japan

🇯🇵

1160.254.81001 Boehringer Ingelheim Investigational Site, Shinagawa, Japan

A Study to Assess the Effect of Multiple-Dose Administration of JNJ-42847922 on Midazolam and Warfarin in Healthy Participants

Phase 1
Completed
Conditions
Interventions
First Posted Date
2015-12-01
Last Posted Date
2016-02-23
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
18
Registration Number
NCT02617810

Assessment of 2012 Bioequivalence Standards for Warfarin

Phase 1
Completed
Conditions
Interventions
First Posted Date
2015-10-14
Last Posted Date
2019-08-05
Lead Sponsor
University of California, San Francisco
Target Recruit Count
10
Registration Number
NCT02574754
Locations
🇺🇸

University of California, San Francisco, San Francisco, California, United States

EdoxabaN or Warfarin Therapy In Device Procedures in Patients With Non-Valvular Atrial Fibrillation

Phase 4
Terminated
Conditions
Interventions
First Posted Date
2015-09-28
Last Posted Date
2020-06-30
Lead Sponsor
Electrophysiology Research Foundation
Target Recruit Count
5
Registration Number
NCT02561897
Locations
🇺🇸

Electrophysiology Research Foundation, Warren, New Jersey, United States

Pleotropic Effect of New Oral Anticoagulants

First Posted Date
2015-09-09
Last Posted Date
2015-09-09
Lead Sponsor
Kyunghee University Medical Center
Target Recruit Count
55
Registration Number
NCT02544932
Locations
🇰🇷

Kyung Hee University, Seoul, Korea, Republic of

A Drug Interaction Study of Lanabecestat (LY3314814) and Warfarin in Healthy Participants

Phase 1
Completed
Conditions
Interventions
First Posted Date
2015-09-04
Last Posted Date
2019-11-04
Lead Sponsor
AstraZeneca
Target Recruit Count
15
Registration Number
NCT02540668
Locations
🇺🇸

Covance Clinical Research Inc, Evansville, Indiana, United States

Drug Interaction Study of Warfarin and MT-3995

Phase 1
Completed
Conditions
Interventions
First Posted Date
2015-08-24
Last Posted Date
2015-10-09
Lead Sponsor
Mitsubishi Tanabe Pharma Corporation
Target Recruit Count
20
Registration Number
NCT02531568
Locations
🇩🇪

Clinical research organization, Neu-Ulm, Wegenerstraße, Germany

Tecarfarin Anti-Coagulation Trial (TACT)

First Posted Date
2015-08-13
Last Posted Date
2018-01-25
Lead Sponsor
Espero Biopharma
Target Recruit Count
1000
Registration Number
NCT02522221

XENITH: Rivaroxaban for Pulmonary Embolism Managed With Catheter Directed Thrombolysis

First Posted Date
2015-07-23
Last Posted Date
2018-09-27
Lead Sponsor
Susan Smyth
Target Recruit Count
10
Registration Number
NCT02506985
© Copyright 2024. All Rights Reserved by MedPath